Salinosporamide A is a β-lactone proteasome inhibitor currently in clinical trials for the treatment of multiple-myeloma. Herein we report a short synthesis of this small, highly functionalized, biologically important natural product that uses an oxidative radical cyclization as a key step and allows for the preparation of gram quantities of advanced synthetic intermediates.
Keywords:
Free Radicals
,Lactones
,Pyrroles
,Biological Products
,Cyclization
,Oxidation-Reduction
,Proteasome Inhibitors
